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Summary: mechanisms mediated by cytokines released from donor-
derived T cells.1,2 Therefore, more detailed identification of
T cell subsets can be an exceptionally good way to eluci-Acute graft-versus-host disease (aGVHD) remains a
major barrier to a wider application of allogeneic bone date the immune mechanism responsible for aGVHD.
Recently accumulating evidence indicates that the Fasmarrow transplantation (BMT). Although this compli-
cation is mainly dependent on donor-derived T lympho- (APO-1; CD95)/Fas-ligand (FasL) system represents an
important cellular pathway responsible for T cell-mediatedcytes, very little information is available concerning the
mechanism of lethality. In this study, we investigated cytotoxicity and the induction of apoptosis in various
tissues.3–5 Fas antigen, which is a 45-kDa cell-surface typeboth the expression of Fas/Fas-ligand (FasL) and lym-
phocyte subset reconstitution in patients who underwent I membrane protein member of the tumor necrosis factor
(TNF)/nerve growth factor receptor family, is expressed notHLA-matched related allogeneic BMT (n 5 16) and
normal donors (n 5 10), and several distinct features only on activated T cells, but also on other tissues such as
liver, heart, lung, skin and gastrointestinal tract.3–6 On thewere observed. First, the reconstitutions of CD31 and
CD561 cells were different between the aGVHD1 and other hand, FasL (known as a 40-kDa TNF-related type II
membrane protein) expression is restricted to the activatedaGVHD2 group. In particular, the percentage of
CD3−CD561 cells was significantly decreased in patients mature T cells after various stimuli, except in the testis,
and binding of FasL to Fas induces apoptosis, indicatingwith aGVHD ( P , 0.01). Second, the expansion of CD81
(P 5 0.01) and CD81 CD282 T cells (P 5 0.03) was a that FasL is a death factor, while Fas is its receptor
mediating the apoptotic signal.3,4,7,8Several reports9,10 havecharacteristic finding in patients with aGVHD. Finally,
we found that the percentages of Fas1CD81, Fas1HLA- suggested that Fas mutations result in a massive upregul-
ation of FasL and could explain thelpr-induced GVHD-DR1 and FasL1 CD81 cells were significantly increased.
Fas antigen was highly coexpressed on most of the lym- like wasting syndrome observed whenlpr bone marrow
derived cells were adoptively transferred to wild-type mice.phocyte subsets, especially on CD81 cells (P , 0.01),
and also, significantly higher coexpression of FasL on However, Fas and FasL expression in aGVHD has not been
further evaluated, and its clinical significance remains to beCD81 cells was found in patients with aGVHD
(P , 0.01). In summary, an increase in the percentage elucidated in humans.
Therefore, we evaluated both the lymphocyte subsetof CD81 cells which express Fas and its ligand in
patients with aGVHD after BMT points to a possible reconstitution and the expression of Fas and FasL on each
lymphocyte subset in order to explore the pathogenesis ofrole for the Fas/FasL pathway in the effector phase of
aGVHD. aGVHD based on Fas/FasL pathway.
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Materials and methods
Patients and donorsAcute graft-versus-host disease (aGVHD) remains a major
complication following allogeneic bone marrow transplan-Between March 1994 and December 1995, 16 consecutive
tation (BMT). Although the tissue damage is caused bypatients who underwent HLA-matched related allogeneic
donor-derived T lymphocytes that recognize antigenic dis-BMT for acute leukaemia at first complete remission were
parities between donor and recipient, the lytic mechanismenrolled into this study. All patients were given a myelo-
leading to lesion formation has not been fully ascertainedablative therapy consisting of fractionated total body
but probably involves several concurrent processes. Theseirradiation (TBI; 165 cGy twice daily for 4 consecutive
include direct interactions between donor cytotoxic T lym-days (total 1320 cGy)) combined with cyclophosphamide
phocytes (CTL) and host target cells, or more indirect(60 mg/kg once daily i.v. for 2 days (total dose
120 mg/kg)). Cyclosporin A and short-course methotrexate
were used for GVHD prophylaxis to all patients. Diagnosis
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skin, gut and liver GVHD. All cases of aGVHD were USA). Freshly isolated PBL were labelled with monoclonal
antibodies against the surface determinants CD3, CD45 (allpathologically proven by skin biopsies which were taken
from the affected sites before any steroid therapy was FITC-conjugated), CD4, CD8, CD14, CD56, HLA-DR
(all phycoerythrin-conjugated) from Becton Dickinsongiven. Because direct cytotoxic effects of chemoradiother-
apy may be difficult to distinguish from the findings of (Mountain View, CA, USA). The FITC-conjugated Fas and
CD28 were purchased from Immunotech (Marseille,aGVHD in the first 3 weeks after BMT,12 we defined
aGVHD when patients showed clinical and pathological France), and affinity-purified mouse anti-human FasL anti-
body was also used (Transduction Lab, Lexington, KY,findings including both epidermal basal-cell apoptosis with
lymphoid infiltration and satellitosis. Also, serial biopsies USA). Quantitative fluorescent analysis of the cells was
performed using a FACScan flow cytometer (Bectonand observations were performed for increasing diagnostic
confidence in patients who developed aGVHD in the first Dickinson) equipped with an argon laser. Green (FITC) or
red (phycoerythrin) fluorescence was selected using 530-3 weeks after BMT. Prednisolone (60 mg/m2 day) was used
for the treatment of aGVHD. Characteristics of patients and 585-nm filters, respectively. Events (at least 30 000)
were recorded in list mode on a Consort 30 program. Cellswith aGVHD (aGVHD+ group) and without aGVHD
(aGVHD− group) are shown in Table 1. There were six falling into the lymphocyte gate were.98% CD14− CD45+
population and a correction for this was made in subsequentmales and 10 females, ages ranged from 18 to 44 years
(mean 28 years). Six patients (37.5%) were aGVHD+ and analyses. Cells stained with isotype-matched FITC- and
phycoerythrin-conjugated antibodies were used as negative10 (62.5%) were aGVHD−. We could not detect any sig-
nificant differences with respect to gender, age and total controls. Using dual-color flow cytometry, we also investi-
gated Fas and FasL expression on each lymphocyte subset.infused cell dose. We did not observe any case of viral
infection after transplantation. All patients had successful
engraftment without any significant treatment-relatedStatistical analysis
complications.
Comparisons between the aGVHD+ and aGVHD− groups
were based on Fisher’s exact test for dichotomized vari-
Surface phenotyping by flow cytometry ables and the non-parametric Mann–WhitneyU test for
continuous variables. A significant difference was definedTo compare the percentages of lymphocyte subsets and the
as aP value,0.05.levels of Fas and FasL expression, venous peripheral blood
sampling was performed immediately after the appearance
of the first sign of aGVHD in the aGVHD+ group, and at
Resultsday 14 or 21 after BM infusion in the aGVHD− group.
Normal values were also established by testing 10 healthy
Different pattern in the reconstitutions of CD3+ anddonors. Peripheral blood lymphocytes (PBL) were isolated
CD56+ cellsby standard Ficoll–Hypaque density gradient centrifugation
(1.077 g/ml) and were adherence depleted twice on plastic In the aGVHD+ and the control groups, the percentages of
CD3+ and CD56+ cells were similar, but we observed ain serum-free medium (AIM V, GIBCO, Grand Island, NY,
Table 1 Characteristics of patients receiving HLA-matched related BMT
UPN Sex/Age Disease Infused cells CMV Days of ANC aGVHD grade/Days of onset Days of Days of Tx
(× 108/R.kg) infection .500/mm3 testing onset
aGVHD+ patients (n= 6)
1 F/20 ALL 4.12 — 12 II (Skin II; Liver I; Gut I)/23 23 24
2 F/18 AML 4.10 — 11 II (Skin II; Liver I; Gut I)/13 13 14
3 M/38 AML 3.99 — 18 I (Skin II; Liver 0; Gut 0)/19 19 26
4 F/35 AML 5.18 — 12 I (Skin II; Liver 0; Gut 0)/17 17 25
5 M/44 AML 2.44 — 13 II (Skin III; Liver I; Gut I)/28 28 29
6 F/26 AML 3.57 — 12 I (Skin II; Liver 0; Gut 0)/15 15 24
aGVHD− patients (n= 10)
7 M/26 ALL 6.73 — 11 0 21
8 F/24 AML 5.18 — 10 0 14
9 F/33 AML 3.79 — 11 0 21
10 F/26 AML 5.47 — 11 0 21
11 M/22 AML 3.46 — 10 0 14
12 F/27 AML 2.79 — 12 0 21
13 F/21 AML 3.05 — 12 0 21
14 M/20 AML 3.99 — 15 0 21
15 M/40 ALL 2.08 — 12 0 21
16 F/24 AML 4.07 — 11 0 21
UPN = unique patient number; CMV= cytomegalovirus; ANC= absolute neutrophil count; aGVHD= acute graft-versus-host disease; Tx= treatment;
M = male; F= female; AML = acute myeloid leukaemia; ALL= acute lymphoblastic leukaemia; R= recipient.
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significant increase in the percentage of CD3+ cells in the aGVHD (26.2± 5.9%) (P = 0.03). In contrast, we did not
observe a significant difference in the percentage ofaGVHD+ group (65.6± 2.7vs42.7± 11.0,P , 0.01). Also,
the percentage of CD56+ cells was lower in the aGVHD+ CD8+ CD28+ cells according to the presence of aGVHD.
There was no statistical correlation between CD8+CD28−group (24.3± 8.2 vs 45.4± 4.7, P , 0.01). By dual-color
flow cytometry, we found that most of the CD56+ cells and CD8+ CD28+ cell reconstitution (Figure 1).
were CD3−, and the percentage of CD3−CD56+ cells was
significantly decreased in patients with aGVHD (16.1± 6.7 Absolute numbers of total leukocytes and lymphocytes,
vs 40.2± 5.8, P , 0.01) (Figure 1). and each lymphocyte subset
We also examined whether there were any differences inExpansion of CD8+ and HLA-DR+ cells in patients with
the absolute numbers of leukocytes and lymphocytesaGVHD
between the aGVHD+ and aGVHD− groups. As shown in
Table 2, total leukocyte counts were significantly decreasedThere was no significant difference between the aGVHD+
and aGVHD− groups in the percentage of CD4+ cells in patients with aGVHD but with a wide range between
individuals (2082± 834 vs 4373± 1646,P = 0.04). Among(22.3± 17.8%vs 28.9± 6.8%, P . 0.05). When compared
with the control group, the proportion of CD4+ cells the lymphocyte subsets, the absolute numbers of CD56+
(194± 119 vs 683± 381, P = 0.01) and CD3−CD56+remained at a relatively low level after BMT regardless of
the occurrence of aGVHD. But there was a high percentage (128± 79 vs 605± 337, P , 0.01) cells were significantly
decreased in the aGVHD+ group, but we did not find anyof CD8+ cells in the aGVHD+ group compared to that in
the aGVHD− group (43.3± 11.9% vs 29.4± 6.2%, significant difference in other lymphocyte subsets.
P = 0.01), and also a significantly increased percentage of
HLA-DR+ cells was shown after BMT, especially in
Table 2 Absolute numbers of WBC, total lymphocytes and eachpatients with aGVHD (83.3± 5.1% vs 67.0± 2.2%,
lymphocyte subset according to the occurrence of aGVHD
P , 0.01) (Figure 1).
aGVHD+ aGVHD− P value
(mean± s.d.) (mean± s.d.)Difference in the subpopulation of CD8+ cells
(n = 6) (n= 10)
As mentioned above, an increase in the percentage of CD8+
WBC 2082± 834 4373± 1646 0.04cells was observed in patients with aGVHD (43.3± 11.9vs
Lymphocyte 795± 491 1505± 839 NS29.4± 6.2, P = 0.01). We further analyzed the CD8+ sub-
CD3+ 522 ± 322 643± 358 NSpopulation based on the expression of the CD28 markerCD56+ 194 ± 119 683± 381 0.01
by using double staining. In our study, we evaluated theCD3+CD56− 457 ± 282 566± 315 NS
CD3−CD56+ 128 ± 79 605± 337 , 0.01percentages of CD8+CD28+ and CD8+ CD28− T subsets
CD4+ 177 ± 109 435± 242 NSwhich were all CD8bright+ cells and excluded NK cells,
CD8+ 345 ± 213 442± 247 NSwhich are CD8dim+ cells. We checked that CD8bright+ cells
CD8+CD28− 318 ± 196 394± 220 NS
were CD3+ (data not shown) and therefore belong to the TCD8+CD28+ 43 ± 27 72 ± 40 NS
cell population. We observed a significant increase in theHLA-DR+ 662 ± 409 1008± 562 NS
percentage of CD8+ CD28− cells in patients with aGVHD


































Figure 1 Different patterns of reconstitution of each lymphocyte subset according to the occurrence of aGVHD. aGVHD= acute graft-versus-host
disease; *P = 0.03; ** P = 0.01; *** P , 0.01.
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Higher expression of Fas and FasL in patients with belong to the classical NK cell population. This finding was
aGVHD consistent with other reports13,14 which suggested that the
percentage of CD3−CD56+ cells was closely associated with
To help elucidate the immune pathogenesis of aGVHD, wethe occurrence of aGVHD. Therefore, the evaluation of theanalyzed the coexpression of Fas or FasL together with thepercentage of CD3−CD56+ cells may be a reliable markerlymphocyte subset markers (CD4, CD8, CD56, HLA-DR). in the diagnosis of aGVHD.Here we found that Fas+CD8+ (35.0± 9.3 vs 13.6± 3.1, Another characteristic finding was the close correlation
P , 0.01), Fas+HLA-DR+ (76.3± 2.5 vs 47.3± 1.2,
between the occurrence of aGVHD and the expansion ofP , 0.01), and FasL+CD8+ (32.2± 6.7 vs 11.4± 2.7,
CD8+ cells. This finding was similar to other reports.14–16P , 0.01) cells were significantly increased in the aGVHD+
However, at present, only a few studies have evaluated thepatients (Figure 2). We also analyzed the proportion of
subsets of CD8+ cells after BMT.14,17,18 To help elucidatethese coexpressing cells on each lymphocyte subset (ie
the role of CD8+ cells, we further analyzed the CD8+ popu-Fas+CD8+/CD8+) according to the occurrence of aGVHD.
lation based on the expression of the CD28 marker by usingFas antigen was highly coexpressed on most of the lympho-
double staining. Our data showed that most of the CD8+cyte subsets, especially on CD8+ cells (81.2± 1.5 vs
cells were composed of CD8+CD28− T cells and the per-47.8± 12.7,P , 0.01), and also, significantly higher coex-
centage of these cell populations was significantly higherpression of FasL on CD8+ cells was shown in patients with
in aGVHD+ patients. On the other hand, we did not findaGVHD (77.1± 13.5 vs 40.4± 13.2, P , 0.01). However,
any significant difference in the percentage of CD8+CD28+Fas or FasL expression on CD4+ cells was not different
cells according to the presence of aGVHD. Also, there wasaccording to the presence of aGVHD (Figures 2 and 3).
no correlation between CD8+CD28− and CD8+CD28+ cells
in our aGVHD+ and aGVHD− patients. Thus, we suggest
that the expansion of CD8+ cells is closely correlated withDiscussion
the increased percentage of CD8+CD28− cells and the
evaluation of these cell populations can also be a reliableThis study examined the pattern of lymphocyte subset
marker closely associated with aGVHD.reconstitution associated with the occurrence of aGVHD
We cannot explain why the percentage of CD3− CD56+and elucidated the pathophysiology of aGVHD based on
NK cells was significantly decreased in aGVHD+ patients.Fas/FasL pathway. We evaluated both the percentages and
However, based on our results, we can postulate that thethe absolute numbers of each lymphocyte subset. Since the
increase of CD8+ and CD8+CD28− T cells may be respon-absolute numbers of total leukocytes and lymphocytes were
sible for the relative decrease of CD3− CD56+ cells, sincehighly variable between individuals and not informative,
these cells are nonoverlapping subsets. Given the apparentwe showed and analyzed our results as percentages. Our
importance of CD28 in T cell costimulation,19,20 the differ-data revealed that the percentage of CD56+ cells was sig-
ential role of CD8+CD28− and CD8+CD28+ T cells in thenificantly decreased in patients with aGVHD compared
immune response is still under discussion.21–24 Koide andwith patients without aGVHD, and most of these cells
Engleman22 first hypothesized that CD8+CD28− T cellsexpressed CD3− by detailed analysis using double immuno-






























Figure 2 Simultaneous expression of Fas/Fas-ligand and CD4/CD8/HLA-DR according to the occurrence of aGVHD. aGVHD= acute graft-versus-
host disease; FasL= Fas-ligand; *P = 0.04; ** P , 0.01.
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Figure 3 Coexpression of Fas or Fas-ligand on each lymphocyte subset according to the occurrence of aGVHD. aGVHD= acute graft-versus-host
disease; FasL= Fas-ligand; *P , 0.01.
cytotoxic cells. However, some recent reports suggested cate T cell activation15,16,30 and Fas or FasL are mainly
expressed on activated lymphocyte populations,3–6 our datathat CD8+CD28− T cells had a more potent cytolytic
activity than CD8+CD28+ T cells.21,23,24 Also, the role of suggest that the activated lymphocyte population may be
significantly increased after BMT, especially in aGVHD+NK cells in human GVHD or graft-versus-leukaemia effect
is controversial.25–29 Dokhelaret al25 reported that a strong patients, and the activated CD8+ cells may play a possible
role as an effector through the Fas/FasL pathway in humancorrelation between high NK values and aGVHD occur-
rence existed. Conversely, according to some reports,27–29 aGVHD. To elucidate the precise role of Fas/FasL pathway
and its effectors, confirmation of the expression of FasL onNK cells did not directly mediate aGVHD but had the
potential to suppress the growth of clonogenic leukaemia CD8+ 28− T cells and Fas on target issues is required,
since the expansion of CD8+ cells was closely correlatedand when activated by cytokines could be directly lytic to
leukaemia cells. From this point of view, it appears reason- with the increased percentage of CD8+CD28− cells in this
study.able to suggest that CD8+ CD28− T cells are one of the
most important effectors in aGVHD. In conclusion, an increase in the percentage of CD8+
lymphocytes that express Fas and its ligand in patients withAccording to Garinet al,14 a decrease in the percentages
of HLA-DQ+ and DR+ monocytes and HLA-DQ+ lympho- aGVHD after BMT points to a possible role for the
Fas/FasL pathway in the effector phase of aGVHD.cytes was closely associated with the occurrence of
aGVHD but the percentage of HLA-DR+ lymphocytes was
similar between the aGVHD+ and aGVHD− groups. How-
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